{
    "nctId": "NCT00088998",
    "briefTitle": "Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Confirmed tumor response (complete or partial) rate as measured by RECIST",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed invasive breast cancer\n\n  * Clinical evidence of metastatic disease\n\n    * No bone metastases as the only evidence of metastasis\n* Measurable disease\n\n  * At least 1 lesion \u2265 2.0 cm by CT scan or MRI OR \u2265 1.0 cm by spiral CT scan\n\n    * Lesions on chest x-ray allowed provided they are clearly defined and surrounded by aerated lung\n  * Clincal lesions only considered measurable when they are superficial (e.g., skin nodules or palpable lymph nodes)\n  * Target lesion must not have been exposed to prior radiotherapy unless disease has progressed since completion of radiotherapy\n  * The following are not considered measurable disease:\n\n    * Bone lesions\n    * Leptomeningeal disease\n    * Ascites\n    * Pleural or pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis or pulmonis\n    * Abdominal masses that are not confirmed and followed by imaging techniques\n    * Cystic lesions\n* No HER2/neu-positive tumors by immunohistochemistry or amplified fluorescence in situ hybridization unless disease has progressed after trastuzumab (Herceptin\u00ae)-containing therapy alone or with antiestrogen hormonal therapy for metastatic disease OR trastuzumab is contraindicated\n* Prior breast cancer allowed\n* No prior or active brain metastases\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* At least 3 months\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 8.0 g/dL\n* No bleeding diathesis or uncontrolled coagulopathy\n\nHepatic\n\n* Bilirubin normal\n* Meets 1 of the following criteria:\n\n  * AST and ALT normal AND alkaline phosphatase \u2264 5 times upper limit of normal (ULN)\n  * AST and ALT \u2264 1.5 times ULN AND alkaline phosphatase \u2264 2.5 times ULN\n  * AST and ALT \u2264 5 times ULN AND alkaline phosphatase normal\n\nRenal\n\n* Creatinine clearance \u2265 30 mL/min\n* No proteinuria OR\n* Protein \\< 1 g by 24-hour urine collection\n* No nephrotic syndrome\n\nCardiovascular\n\n* No uncontrolled hypertension (i.e., blood pressure \\> 160/90 mm Hg on \u2265 2 different observations \u2265 5 minutes apart)\n\n  * Blood pressure \\< 140/90 mm Hg on \u2265 3 different observations over \u2265 14 days, for patients who recently began or adjusted anti-hypertensive medication\n* No atrial or venous thrombosis within the past month\n* No clinically significant heart disease, including any of the following:\n\n  * Congestive heart failure\n  * Symptomatic coronary artery disease\n  * Uncontrolled cardiac arrhythmias\n  * Unstable angina\n* No myocardial infarction within the past 12 months\n* No history of cerebrovascular accident\n\nPulmonary\n\n* No hemoptysis within the past 6 months\n\nGastrointestinal\n\n* No lack of physical integrity of the upper gastrointestinal tract\n* No malabsorption syndrome\n* Able to receive oral medication\n\nOther\n\n* No other stage III or IV invasive malignancy requiring treatment within the past 5 years\n* No pre-existing peripheral neuropathy \\> grade 1\n* No history of allergy or hypersensitivity to study drugs, agents that are chemically similar to study drugs, or drugs that contain polysorbate 80\n* No prior severe reaction to fluoropyrimidines\n* No known hypersensitivity to fluorouracil\n* No known dihydropyrimidine dehydrogenase deficiency\n* No active infection\n* No significant medical condition that would preclude study participation\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 30 days after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* See Disease Characteristics\n* No other concurrent biologic therapy\n\nChemotherapy\n\n* Prior adjuvant or neoadjuvant chemotherapy allowed for primary disease\n* No prior chemotherapy for metastatic disease\n* More than 4 weeks since prior cytotoxic chemotherapy\n* More than 6 months since prior taxanes (e.g., docetaxel or paclitaxel)\n* No other concurrent chemotherapy\n\nEndocrine therapy\n\n* See Disease Characteristics\n* Prior antiestrogen hormonal therapy allowed in the adjuvant or metastatic setting\n\nRadiotherapy\n\n* See Disease Characteristics\n* More than 4 weeks since prior radiotherapy to a target lesion\n\n  * Prior single-dose palliative radiotherapy allowed within the past 4 weeks\n* No concurrent radiotherapy\n\nSurgery\n\n* More than 4 weeks since prior major surgery\n\nOther\n\n* More than 2 weeks since prior aspirin, anticoagulants, or thrombolytic agents\n\n  * Concurrent low-dose warfarin (1 mg/day) to maintain patency of vascular access device allowed\n* More than 4 weeks since prior investigational agents\n* No concurrent aspirin, anticoagulants, or thrombolytic agents\n* No concurrent participation in another clinical trial involving investigational agents or procedures",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}